Investor's Business Daily on MSN
Psychedelics-tied GH skyrockets on FDA go-ahead for depression drug
Biotech stock GH Research catapulted Monday after the FDA gave it the go-ahead to resume testing its depression drug.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results